Go back

Queensland partners biopharma giant on next-generation medicines

The University of Queensland is partnering the world's largest biopharmaceutical company to develop next-generation medicines for the treatment of major diseases.

David Craik and David Fairlie from Queensland’s Institute for Molecular Bioscience have received AU$2.5 million from the Australian Research Council to partner Pfizer in developing peptide-based medicines that will help overcome the limitations of existing treatments for diseases such as diabetes and cardiovascular disease.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.